Amylin Pharmaceuticals to Present at Research & Development Day
November 21 2007 - 7:00AM
PR Newswire (US)
SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at its
Research & Development (R&D) Day on Wednesday, November 28,
2007 at 10:00 a.m. ET at the Grand Hyatt Hotel in New York. "Amylin
is focused on bringing innovative medicines with life-changing
therapeutic potential to patients through our sustainable approach
to the discovery and development of drugs," said Daniel M.
Bradbury, President and Chief Executive Officer of Amylin
Pharmaceuticals. "At this year's R&D Day, we look forward to
presenting an update on our opportunities to build near-term value
with our marketed products, discussing our recent exciting clinical
results from the once-weekly exenatide program and the
pramlintide/leptin program, and providing insights into our
research strategy." The agenda for this year's R&D Day includes
presentations by the following officers of Amylin Pharmaceuticals:
-- Introduction Daniel M. Bradbury President and Chief Executive
Officer -- Diabetes Programs Orville Kolterman, MD Senior Vice
President of Clinical and Regulatory Affairs -- Obesity Programs
Alain Baron, MD Senior Vice President of Research -- Discovery
Research Michael Hanley, PhD Vice President of Discovery Research A
question and answer session will follow the presentations. The
presentation will be webcast live through Amylin's corporate
website and a recording will be made available following the close
of the call. To access the webcast, please log on to
http://www.amylin.com/ approximately fifteen minutes prior to the
call to register, download and install any necessary audio
software. About Amylin Pharmaceuticals Amylin Pharmaceuticals, Inc.
is a biopharmaceutical company committed to improving lives through
the discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two first-
in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research
and development activities leverage the company's expertise in
metabolism to develop potential therapies to treat diabetes and
obesity. Amylin is headquartered in San Diego, California with over
1,800 employees nationwide. Further information on Amylin
Pharmaceuticals is available at http://www.amylin.com/. DATASOURCE:
Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner Izzo of Amylin
Pharmaceuticals, Inc., +1-858-642-7272, Cell, +1-858-232-9072, ; or
Rachel Martin of Edelman, +1-323-202-1031, Cell, +1-323-373-5556, ,
for Amylin Pharmaceuticals, Inc. Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024